Cantor Fitzgerald analyst Charles Duncan raised the firm’s price target on Axsome Therapeutics to $96 from $88 and keeps an Overweight rating on the shares. Axsome reported Q3 revenue of $16.8M, which was in line estimates, Duncan tells investors in a research note. Axsome had a very productive quarter, highlighted by the approval of AUVELITY for MDD, and the analyst envisions AUVELITY becoming a mainstay.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM: